Sweden's Immunovia Q1 net sales rise, cash burn falls below guidance

Immunovia AB (publ)

07/05/2026 07:38

Overview

Sweden diagnostic firm's Q1 net sales rose yr/yr, operating loss narrowed slightly

Company's Q1 cash burn rate fell below guidance due to lower clinical study spending

Reverse share split proposal withdrawn after major shareholder feedback

Outlook

Company did not provide specific financial or operational guidance for the current or future periods

Result Drivers

REGULATORY APPROVALS - Co received approval to sell PancreaSure in California, Maryland, Rhode Island, and Washington, D.C., expanding access to 49 of 50 US states

SALES TEAM EXPANSION - Co assembled initial sales team, hiring three Strategic Account Managers with diagnostics experience

PAYER BILLING INITIATED - Co began billing private insurers for PancreaSure tests, though payer revenue expected to be limited until coverage is achieved

Company press release: ID:nMFN36Y7Fl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
-SEK 0.03


Analyst Coverage

Wall Street's median 12-month price target for Immunovia AB (publ) is SEK0.48, about 174% above its May 6 closing price of SEK0.18

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)